Daphaelson Tablets 5 mg (Dapagliflozin anhydrous mixture)
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
EriSon Pharmaceutical Co., Ltd.
MFDS item code 202005374 · Approved 2020.07.23
This product's status changed to Expired on 2025.07.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to assist in blood sugar control for patients with type 2 diabetes. It can be administered alone or in combination with other medications, alongside dietary and exercise therapy. It is particularly beneficial for patients with type 2 diabetes who have cardiovascular diseases or risk factors when blood sugar is poorly controlled. This medication contributes to the effective management of blood sugar and helps prevent complications. Therefore, it is used in the treatment and blood sugar control of type 2 diabetes.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this drug is 10mg once daily for monotherapy and add-on combination therapy with other blood glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received pharmacological treatment for diabetes, when administered in combination with metformin, the recommended initial dose of this drug is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR below 45 mL/min/1.73m2 : Administration of this drug is not recommended for the purpose of improving glycemic control. - Patients on dialysis : Do not administer this drug. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This drug may be administered orally once daily at any time of the day, with or without food. The tablet should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used in patients who have had allergic reactions to the active ingredients or excipients in this drug. It should also not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Furthermore, patients with lactose intolerance or specific genetic issues leading to inability to digest lactose may have problems due to the included anhydrous lactose and thus should not receive this drug. This medication is not suitable for patients undergoing dialysis. For patients who have reduced fluid volume or issues with kidney function, this medication should be used with caution. It can cause hypotension or worsening of renal function, so these patients should have their fluid status and kidney function carefully monitored before and after administration. In particular, for patients with moderate to severe renal impairment, the effectiveness of blood sugar control may decrease, and it may be difficult to achieve blood sugar control with this medication alone. This medication contains coloring agents Yellow No. 4 and Yellow No. 5, so those who have allergies or hypersensitivity to these agents should use it cautiously. During the use of this medication, genital infections or urinary tract infections may occur, so if related symptoms arise, prompt treatment should be received. Hypoglycemic symptoms may also be present, especially when used with medications like insulin or sulfonylureas, where the risk may be heightened. Dehydration or hypotensive symptoms may occur due to decreased fluid volume, so if symptoms such as dizziness or dry mouth occur, consultation with healthcare professionals is necessary. There is a risk of serious metabolic abnormalities like diabetic ketoacidosis, so if symptoms such as vomiting, abdominal pain, or difficulty breathing occur, immediate medical attention should be sought. This medication may have renal-related adverse reactions like elevated blood creatinine due to changes in kidney function, so regular blood tests are necessary. Especially for the elderly or those with diminished kidney function, greater caution should be exercised when using this medication, and dosage adjustment or discontinuation should be considered as needed. It is recommended that women who are pregnant or breastfeeding do not use this medication, and if pregnancy is confirmed, it should be discontinued immediately. This medication does not significantly affect driving or the ability to operate machinery; however, caution is needed when used with drugs that have a risk of hypoglycemia.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to protect it from air and moisture. It is best to maintain the storage temperature between 1 and 30 degrees Celsius at room temperature. This will help preserve the medication's effectiveness for a longer duration.
Yellow, round, biconvex film-coated tablets
28 tablets/box [14 tablets/PTP x 2, 7 tablets/PTP x 4]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
EriSon Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.